Metformin
- Generic Name
- Metformin
- Brand Names
- Actoplus Met, Avandamet, Fortamet, Glucophage, Glucovance, Glumetza, Glycon, Invokamet, Janumet, Jentadueto, Kazano, Kombiglyze, Komboglyze, Qternmet, Riomet, Segluromet, Synjardy, Trijardy, Velmetia, Xigduo
- Drug Type
- Small Molecule
- Chemical Formula
- C4H11N5
- CAS Number
- 657-24-9
- Unique Ingredient Identifier
- 9100L32L2N
- Background
Metformin is a biguanide antihyperglycemic agent and first-line pharmacotherapy used in the management of type II diabetes.
Metformin is considered an antihyperglycemic drug because it lowers blood glucose concentrations in type II diabetes without causing hypoglycemia. It is commonly described as an "insulin sensitizer", leading to a decrease in insulin resistance and a clinically significant reduction of plasma fasting insulin levels. Another well-known benefit of this drug is modest weight loss, making it an effective choice for obese patients type II diabetes.
Metformin was first approved in Canada in 1972, and received subsequent FDA approval in the US in 1995.
- Indication
Metformin immediate-release formulations
Metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients ≥10 years old with type 2 diabetes mellitus.
Metformin extended-release tablet (XR)
The extended-release formulation of metformin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Safety in children has not been determined to this date.
Metformin combination products
Metformin is a component of a variety of combination products with other anti-diabetic agents. It is indicated, along with diet and exercise, to improve glycemic control in adult patients with type 2 diabetes mellitus in combination with DPP-4 inhibitors (sitagliptin, linagliptin, alogliptin, or saxagliptin), in combination with SGLT2 inhibitors (canagliflozin, empagliflozin, ertugliflozin, or dapagliflozin), or in combination with pioglitazone.
- Associated Conditions
- Cardiovascular Mortality, End Stage Renal Disease (ESRD), Hospitalizations, Polycystic Ovarian Syndrome (PCOS), Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate
- Associated Therapies
- -
Effect of Oral Combination Therapy in a Single Dosage Form in Patients With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2009-07-17
- Last Posted Date
- 2010-05-18
- Lead Sponsor
- Laboratorios Silanes S.A. de C.V.
- Target Recruit Count
- 28
- Registration Number
- NCT00941161
- Locations
- 🇲🇽
Centro Universitario de Ciencias de la Salud. Universidad de Guadalajara, Guadalajara, Jalisco, Mexico
Study on DMMET-01 Versus Metformin on Improvement of Metabolic Control in Naive Type 2 Diabetes Patients
- First Posted Date
- 2009-07-16
- Last Posted Date
- 2010-05-18
- Lead Sponsor
- Laboratorios Silanes S.A. de C.V.
- Target Recruit Count
- 20
- Registration Number
- NCT00940472
- Locations
- 🇲🇽
Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jal, Mexico
Glycemic And Blood Pressure Control In Type 2 Diabetes, In A Primary Care Unit: A Staged Management Strategy
- First Posted Date
- 2009-07-09
- Last Posted Date
- 2011-10-26
- Lead Sponsor
- Hospital de Clinicas de Porto Alegre
- Target Recruit Count
- 124
- Registration Number
- NCT00935805
- Locations
- 🇧🇷
Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil
Pre-Surgical Study: Effect of Metformin on Breast Cancer Proliferation
- First Posted Date
- 2009-06-30
- Last Posted Date
- 2022-10-20
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 35
- Registration Number
- NCT00930579
- Locations
- 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
Sitagliptin/Metformin Fed Bioequivalence Study (0431A-080)
- Conditions
- Interventions
- First Posted Date
- 2009-06-26
- Last Posted Date
- 2015-08-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 61
- Registration Number
- NCT00929201
Comparative Study of HOE490 O (Glimepiride and Metformin) Compared With Placebo on Top of Glimepiride
- Conditions
- Interventions
- First Posted Date
- 2009-06-19
- Last Posted Date
- 2011-08-31
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 189
- Registration Number
- NCT00924573
- Locations
- 🇯🇵
Sanofi-Aventis Administrative Office, Tokyo, Japan
Treatment of Type 2 Diabetes With Linagliptin 2.5 mg Bid + Metformin 500 or 1000 mg Bid and Metformin 1000 mg Bid
- Conditions
- Interventions
- First Posted Date
- 2009-06-08
- Last Posted Date
- 2014-05-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 567
- Registration Number
- NCT00915772
- Locations
- 🇨🇦
1218.52.11003 Boehringer Ingelheim Investigational Site, Edmonton, Alberta, Canada
🇨🇦1218.52.11002 Boehringer Ingelheim Investigational Site, Red Deer, Alberta, Canada
🇭🇷1218.52.38502 Boehringer Ingelheim Investigational Site, Karlovac, Croatia
Efficacy and Safety of Adjuvant Metformin for Operable Breast Cancer Patients
- First Posted Date
- 2009-05-28
- Last Posted Date
- 2015-07-29
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 105
- Registration Number
- NCT00909506
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
A 12 Week Study in Patients With Type 2 Diabetes Mellitus (T2DM)
- Conditions
- Interventions
- First Posted Date
- 2009-05-14
- Last Posted Date
- 2013-01-09
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 693
- Registration Number
- NCT00901979
- Locations
- 🇺🇸
Metabolic Research Institute, Inc., West Palm Beach, Florida, United States
🇺🇸John Muir Clinical Research, Concord, California, United States
🇺🇸Dallas Diabetic and Endocrinology Research Center, Dallas, Texas, United States
Dose Finding, Safety and Efficacy of Monthly Subcutaneous Canakinumab Administration in Metformin Monotherapy Treated Type 2 Diabetic Patients
- Conditions
- Interventions
- First Posted Date
- 2009-05-12
- Last Posted Date
- 2012-02-20
- Lead Sponsor
- Novartis
- Target Recruit Count
- 556
- Registration Number
- NCT00900146
- Locations
- 🇦🇷
Centro de Investigaciones Clinicas del Litoral, Santa Fe, Argentina
🇵🇪Clinica Chiclayo, Chiclayo, Peru
🇮🇳King George Hospital, Visakhapatnam, India
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.